Zidalev

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zidalev

Property Description
Active Ingredient Levofloxacin (INN)
Primary Forms Oral Tablet, Solution for Injection, Ophthalmic Solution
Pharmacological Class Fluoroquinolone Antibiotic (Third-Generation)
General Purpose Management of systemic or localized bacterial infections
Origin / Status Synthetic, Prescription-only

What Type of Antibiotic is Zidalev (Levofloxacin)?

Zidalev is a prescription-only medicine defined by its active pharmaceutical ingredient, levofloxacin, which is a synthetic antibacterial agent belonging to the fluoroquinolone antibiotic group. This classification is clinically recognized for its role in infection management. Levofloxacin is further categorized as a third-generation quinolone antibiotic, a status derived from its advanced structure and broad activity. As a single active ingredient product, Zidalev is designed for targeted use against a wide spectrum of susceptible bacterial infections.

The Chemical Difference: Why is Levofloxacin a Unique Fluoroquinolone?

Its chemical structure is highly specific: levofloxacin is the purified S-(-) optical isomer of the older compound, ofloxacin, which is a racemic mixture. This distinction is key, as purifying the S-(-) isomer maximizes the therapeutically active component, providing an enhanced and targeted bactericidal effect. This specificity is intended to effectively interfere with bacterial processes. Its primary function is to manage the progression of bacterial diseases through the inhibition of bacterial DNA synthesis.

How is Levofloxacin Classified and Presented?

Zidalev, based on its active ingredient levofloxacin, is available in several dosage forms to accommodate patient needs, illustrating its versatility in clinical settings. The preparations include oral tablets and an oral solution intended for systemic absorption, as well as a sterile solution for injection for intravenous use. A distinct feature is the availability of an ophthalmic solution (eye drops), which permits topical administration. This range of forms ensures that levofloxacin can be appropriately delivered to treat either systemic infections deep within the body or localized bacterial infections on the eye's surface.

What side effects are possible with Zidalev?

Possible side effects and safety information

The safety profile of Zidalev (levofloxacin) is formally documented in government-approved prescribing information, outlining adverse reactions grouped by the physiological system affected and their reported frequency. Safety classifications are typically organized into tiers ranging from Common to Not Known.


Classification of Officially Documented Adverse Reactions

Common Reactions (occurring in 1 to 10 out of 100 patients) are primarily associated with the Gastrointestinal and Nervous System-Organ Classes, and typically include nausea, diarrhoea, headache, dizziness, and insomnia.

Rare Reactions (occurring in 1 to 10 out of 10,000 patients) involve more serious, system-specific effects. These include tendinitis, severe hypoglycemia (low blood sugar), and Central Nervous System disorders such as convulsions, depression, and peripheral neuropathy.


Documented Serious Adverse Reactions and Systemic Concerns

The official label lists several serious adverse reactions affecting multiple body systems. These include tendon rupture, aortic dissection or aneurysm, and severe reactions involving the nervous system like peripheral neuropathy, which may begin rapidly. Cardiac risks include QT interval prolongation, which can lead to a serious arrhythmia. Rare but severe skin reactions, such as Stevens-Johnson syndrome (SJS), are also documented.

Population-Specific Safety Considerations

The risk of tendon disorders and aortic risks is officially noted as increased in older adults. For diabetic patients, there is an increased risk of severe hypoglycemia. Furthermore, use in children and adolescents is restricted due to the potential for musculoskeletal issues.

Overdose and Emergency Response

Overdose and when to seek help — Official Regulatory Information for Zidalev

Overdose Scope

Property Official Regulatory Statement
Documented overdose presentations Overdose is documented to present with severe Central Nervous System (CNS) effects including convulsions, acute confusional states, hallucinations, and tremor. Cardiovascular signs such as palpitation and tachycardia are also described.
Physiological systems affected (as stated in label) The primary systems affected include the Central Nervous System, Cardiovascular System (risk of fatal arrhythmias), and the Metabolic System (risk of hypoglycaemic coma).
Dose-related or exposure-related factors (if applicable) Overdose manifestations are associated with exposure to doses significantly exceeding the maximum recommended therapeutic level.
Population-specific overdose notes (if applicable) Increased risk of complications is noted in the elderly (potential for QT prolongation and severe hepatotoxicity) and in patients with renal impairment (due to decreased clearance).
Emergency-response statements (as written in official documents) Patients must seek emergency medical attention immediately, or call the Poison Help line. Immediate discontinuation of the medicine is required upon the first appearance of serious reactions.
When immediate medical help is required (label-derived phrasing only) Urgent help is required for any suspected overdose, onset of severe symptoms, or signs of aortic events (e.g., sudden severe chest or back pain) or cardiac events (e.g., new onset heart palpitations).

Overdose Classifications (High-Level)

Property Official Regulatory Statement
Severity classification (as defined in official documents) Classified as potentially resulting in life-threatening or severe outcomes, including Cardiac Arrest, Torsade de Pointes, and Hypoglycaemic Coma.
Regulatory basis (EMA / FDA / etc.) Based on official labeling and safety documents (Summary of Product Characteristics and Prescribing Information).
Overdose-context constraints (as defined in official documents) Management is restricted to symptomatic and supportive treatment; no specific antidote is documented in the official prescribing information.

Resulting Overdose Structure

Official overdose statements:

  • Overdose may lead to severe CNS manifestations, including convulsions and acute confusional states.
  • Severe overdose carries the risk of life-threatening cardiotoxicity, including QT interval prolongation and Torsade de Pointes, potentially leading to Cardiac Arrest.
  • Official instructions mandate that patients must seek emergency medical attention immediately for any suspected overdose or onset of severe symptoms.
  • Management procedures include implementing symptomatic and supportive treatment and utilizing ECG monitoring for cardiac risk assessment.
  • Patients with renal impairment or who are elderly are explicitly noted to be at increased risk of complications in overdose scenarios.

Connection to the overall overdose profile (2-4 sentences): The regulatory documents define the Zidalev overdose profile primarily by the risk of severe CNS toxicity and life-threatening cardiovascular events. This framework explicitly dictates that the absence of a specific antidote necessitates the immediate seeking of emergency medical help for supportive management and continuous observation. The officially stated manifestations and outcomes determine the absolute triggers for regulator-mandated emergency action.

Therapeutic Uses of Zidalev

Zidalev (Levofloxacin) may be part of symptomatic management for bacterial infections that present with disruptive symptom manifestations across several key body systems, providing support that helps ease the overall symptom burden.

Zidalev is primarily applied across domains where additional symptomatic support is needed. This includes conditions presenting with systemic or localized discomfort, such as pneumonia, episodes where symptoms become more disruptive during flare-ups of existing respiratory conditions, complicated urinary tract infections (including pyelonephritis), prostatitis, and deep skin layer infections.

The medicine is relevant in contexts marked by increased discomfort and is used for managing symptom clusters like fever, discharge, severe pain, and symptoms linked to organ-specific functional stress.

Quick Fact: Support for Symptom Load
Zidalev may help with improving day-to-day comfort when managing symptoms that create noticeable functional strain during difficult symptomatic periods.

In highly specific, critical scenarios, Zidalev is considered relevant for easing conditions marked by increased physiological stress, which may include post-exposure management of inhalational anthrax and the treatment of plague. The medicine may assist with maintaining a sense of stability and supports patients during difficult episodes across these diverse therapeutic areas.

Eligibility and Restrictions for Use

Official Eligibility and Non-Eligibility for Zidalev (Levofloxacin)

The ability to use Zidalev is determined by specific rules established in regulatory prescribing information, focusing on patient population and pre-existing conditions.

Contraindications (Must Not Use)

Contraindicated Group Restriction Basis
Allergy/Hypersensitivity Known reaction to levofloxacin or other quinolone antibiotics.
Tendon History Previous tendon disorder related to a fluoroquinolone.
Pediatric/Adolescent General use in children and growing adolescents is prohibited.
Pregnancy/Lactation Prohibited for use during pregnancy and breastfeeding.
Epilepsy Patients with a history of epilepsy.

Restricted or Conditional Use

The medicine is generally approved for adults (ge 18 years of age). However, eligibility requires special caution in several populations:

  • Renal Impairment: Patients with a creatinine clearance below 50 mL/min are not excluded but require a mandatory dose adjustment due to impaired drug clearance.
  • Myasthenia Gravis: Use is not recommended due to the potential for muscle weakness exacerbation.
  • Older Adults and Transplant Recipients: Special caution is advised for patients over 60 or those with a history of organ transplants due to increased tendon injury risk.
  • Pediatric Use: Use in children is strictly limited to specific, life-threatening infections, such as Inhalational Anthrax (post-exposure) and Plague, starting from ge 6 months of age.

What should I know about interactions with other medicines?

Zidalev Interactions with other medicines and products

Interactions with Zidalev (levofloxacin) are primarily structured around its absorption and elimination pathways, as documented in official regulatory information. These documented interactions establish specific requirements for co-administration with certain substances.


Pharmacokinetic and Pharmacodynamic Interactions

Mechanism / Effect Interacting Substances (Official Documentation)
Reduced Absorption (Chelation) Multivalent Cations (e.g., antacids, sucralfate, didanosine, mineral supplements)
Reduced Renal Clearance Probenecid and Cimetidine
Enhanced Effect (Anticoagulation) Warfarin (requires INR/PT monitoring)
Increased Cardiac Risk (Additive QT Prolongation) Drugs that Prolong the QT Interval (e.g., Class IA and Class III antiarrhythmics)
Blood Glucose Fluctuation Antidiabetic Agents (requires blood glucose monitoring)

Requirements for Co-administration

The absorption interference from multivalent cations requires oral Zidalev to be taken at least two hours before or two hours after these products. This separation is mandatory to ensure adequate systemic drug exposure. Medicines that affect renal tubular secretion, such as Probenecid and Cimetidine, are officially documented to reduce levofloxacin clearance, potentially increasing systemic levels. Furthermore, regulatory documents note that the risk of tendinopathy/tendon rupture is increased in the elderly when Zidalev is used concurrently with corticosteroids.

Mechanism of Action

Dual Inhibition of Bacterial DNA Maintenance Enzymes

Zidalev acts by engaging two critical bacterial enzymes, DNA Gyrase (Topoisomerase II) and Topoisomerase IV, which are responsible for maintaining the correct physical structure of bacterial DNA. The levofloxacin molecule forms a lethal, trapped ternary complex with the enzyme and the DNA, effectively poisoning the enzyme. This mechanism initiates or suppresses signaling sequences that lead to downstream effects, modulating core microbial processes.


The Irreversible Bactericidal Cascade

By inhibiting DNA Gyrase, Zidalev prevents the necessary unwinding and coiling (supercoiling) of the bacterial chromosome, which is essential for replication. By inhibiting Topoisomerase IV, it blocks the separation of newly replicated chromosomes. This combined molecular sabotage leads to overwhelming, irreparable DNA double-strand breaks, modifying early molecular steps that shape cellular outcomes. This cellular disruption results in a bactericidal effect, which leads to the clearing of susceptible microbial populations.


Mechanisms of Functional Constraint

The drug's mechanism is physiologically constrained when bacteria develop ways to limit its action. This occurs primarily through target-mediated resistance, where genetic mutations in the target enzymes (GyrA, ParC) reduce the drug's binding affinity. Additionally, some bacteria can activate efflux pumps that actively expel the drug from the cell. These mechanisms prevent the required intracellular concentration from being reached, resulting in compromised target inhibition and a reduced bactericidal effect.

Dosage and Administration Information

Official Administration Guidelines for Zidalev

Zidalev (Levofloxacin) is used according to strict guidelines defined by regulatory labeling, which governs the delivery method, dose quantity, and schedule. The medicine is approved for Oral (tablet, solution), Intravenous (IV) Infusion, and Topical (Ophthalmic) routes of administration; the IV preparation is not for routes like intramuscular or subcutaneous delivery.

Dosage and Frequency

Systemic dosing for adults is consistently once daily, with the specific dose determined by the type of condition being addressed, typically 250 mg, 500 mg, or 750 mg. For certain pediatric uses related to anthrax or plague, a twice-daily, weight-based regimen is specified. Treatment durations are also defined by the label, ranging from as short as three days to a prolonged 60-day course for post-exposure management.

Administration Conditions

Oral tablets can be taken without regard to food, while the oral solution is generally recommended to be taken apart from meals. A critical administration constraint involves timing: Zidalev must be taken at least two hours before or two hours after the ingestion of products containing multivalent cations, such as iron supplements or antacids, to ensure proper absorption. Intravenous administration requires slow infusion, taking a minimum of 60 minutes for a 500 mg dose. Dose adjustments are mandated for adult patients with moderate to severe renal impairment (Creatinine Clearance <50 mL/min), often requiring a reduced dose or extended interval.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zidalev (Levofloxacin)


Evidence for Use in Common Systemic Bacterial Infections (Pneumonia and Bronchitis)

Clinical research has extensively explored Zidalev's use in adult patients diagnosed with Community-Acquired Pneumonia (CAP) and acute flare-ups of chronic respiratory conditions. These large studies often used a randomized, controlled design, where Zidalev was observed in populations and compared against other established antibiotics. Researchers in these trials monitored several outcomes related to systemic or functional imbalance, including the microbiological status and the overall clinical status.

Trials reported measured clinical outcomes and microbiological status at the end-of-therapy follow-up visits. The data collected in Phase 3 and 4 trials reported measured clinical outcomes in the context of active comparator treatments. What remains uncertain is the need for research exploring short-term symptom changes to continually track the emergence of resistance in prevalent respiratory pathogens.


Evidence for Infections of the Urinary Tract and Skin Structures

For complicated infections of the urinary tract (cUTI), Zidalev was evaluated in numerous global RCTs involving adult patients with upper tract infections. The primary research goals examined outcomes linked to inflammatory or irritative states and the physical clearance of bacteria. Studies monitored both the microbiological status in urine cultures and the overall clinical status at follow-up.

Trials reported that a majority of microbiologically evaluable patients were classified using the composite study endpoint at the designated follow-up visit. In Chronic Bacterial Prostatitis, Zidalev was studied for its ability to clear the causative organism over long treatment courses, with studies reporting that clinical outcomes appear to be tied to the initial clearance of the bacteria. A key research limitation is that variable local resistance rates of common uropathogens introduce uncertainty regarding the drug's applicability in specific local settings.

Key Studies & References

  1. U.S. National Library of Medicine (DailyMed) overview for Levofloxacin

Frequently Asked Questions (FAQ)

Common questions about Zidalev (FAQ)


Q: What are the most common things people feel when they first start taking Zidalev?

Official documents classify common reactions as including nausea, headache, dizziness, and trouble sleeping (insomnia). According to regulatory warnings, certain serious reactions, such as tendinitis (tendon inflammation), have been reported to occur as early as within 48 hours of starting treatment. Awareness of how the body responds to the medicine is generally part of receiving the medicine.


Q: Is Zidalev the same type of medicine as [similar drug name]?

Zidalev is the brand name for the active ingredient, levofloxacin, which is classified as a synthetic antibacterial agent belonging to the fluoroquinolone antibiotic group. Its chemical structure is specifically identified as the S-(-) optical isomer of the older antibiotic, ofloxacin.


Q: Is it normal to feel tired in the first week of taking Zidalev?

The official safety profile includes general body weakness, or fatigue (also referred to as asthenia), as a possible adverse reaction. Furthermore, official safety warnings mention fatigue among the symptoms that may be associated with long-lasting effects of fluoroquinolones.


Q: Does Zidalev affect sleep patterns?

Yes, official safety data indicates that Zidalev can affect sleep. Insomnia (difficulty falling or staying asleep) is classified as a common adverse reaction. More serious sleep disorders have also been listed among the reported side effects of this class of medicine.


Q: If I miss a dose of Zidalev, what is the official guidance?

Regulatory guidance describes that a patient may take the dose as soon as it is remembered, unless it is almost time for the next scheduled dose. If it is almost time for the next dose, the missed dose should be skipped entirely. Official guidance strictly specifies not to take a double dose to make up for a forgotten one.


Q: What should I do if a side effect of Zidalev seems mild?

For common, mild side effects, the patient's regulatory guidance is to discuss the symptoms with their healthcare provider if the symptoms persist or become bothersome. For severe or specific reactions, such as tendon pain or numbness, immediate medical attention and discontinuation of the drug is mandated by official warnings.


Q: Can I take Zidalev if I am taking supplements like vitamins or herbal remedies?

Official documents contain a critical warning that levofloxacin absorption is significantly reduced when taken concurrently with products containing divalent or trivalent cations. This includes substances such as iron salts, zinc salts, or magnesium- or aluminum-containing antacids (often found in mineral supplements). Regulatory documents describe a required separation by at least two hours between taking Zidalev and these specific supplements to maintain proper absorption.


Q: Can Zidalev be crushed or split if a person has trouble swallowing?

The official administration guidelines specify that Zidalev tablets are taken orally, but they do not contain any instructions or recommendations regarding crushing, cutting, or splitting the tablet formulation. The availability of other forms, such as the oral solution, is a matter for discussion with a healthcare professional.


Q: Why is Zidalev sometimes stopped suddenly and sometimes tapered?

Official regulatory warnings mandate that treatment with levofloxacin must be immediately discontinued at the first sign of certain serious adverse reactions, such as the initial signs of tendinitis or convulsive seizures. The full course of treatment and discontinuation procedures are matters for clinical judgment.


Q: What happens if I accidentally take two Zidalev pills at once?

The regulatory information for administration specifies not to take a double dose. Official documents describing overdose report central nervous system symptoms such as confusion, dizziness, and convulsive seizures, as well as cardiac rhythm changes. Accidental ingestion beyond the prescribed amount is a matter for discussion with a healthcare professional.


Q: Does Zidalev have a warning about driving or operating machinery?

Yes, official patient information contains warnings that Zidalev may affect coordination, reaction time, or judgment due to potential side effects like dizziness. Patients are advised to exercise caution regarding driving or operating machinery until they are aware of how the medicine affects them.


Q: Is Zidalev a long-term treatment or a short-term one?

The official prescribing information defines various treatment durations depending on the infection being managed, which can range from three days to a prolonged 60-day course. Regulatory warnings indicate the medicine is generally reserved for severe bacterial infections and is not recommended for mild infections.


Q: Are there any specific foods to avoid while on Zidalev?

The administration guidelines state that Zidalev tablets can be taken without regard to food. However, it is officially required that the tablets be separated by at least two hours from products containing multivalent cations (e.g., iron, zinc, or magnesium/aluminum antacids), which are common supplements.


Q: Can Zidalev be used by children?

General use of Zidalev is prohibited for children and growing adolescents due to the risk of musculoskeletal issues. Official regulatory documents strictly limit its use in children (ge 6 months of age) to specific, life-threatening bacterial infections, such as Inhalational Anthrax (post-exposure) and Plague.


Q: Do lifestyle factors like smoking or alcohol affect Zidalev's effectiveness?

The official patient information advises that consuming alcohol with Zidalev can increase the risk of side effects such as dizziness or fainting. Regulatory information suggests discussing the use of the medicine with alcohol or tobacco consumption with a healthcare professional. The impact of these factors on the medicine’s overall effect is a matter for discussion with a healthcare professional.


Q: How long does Zidalev stay in your system after stopping treatment?

The mean terminal plasma elimination half-life of levofloxacin, the active ingredient in Zidalev, is described in official pharmacokinetic studies as ranging from approximately 6 to 8 hours. This half-life is the time it takes for half of the drug to be cleared from the body.


Q: Why do doctors choose Zidalev over other medicines for the same condition?

Zidalev is classified as a synthetic antibacterial agent of the fluoroquinolone class. Its approved uses are for the management of specific, susceptible bacterial infections, a role recognized by the World Health Organization's Model List of Essential Medicines.


Q: Are the side effects of Zidalev temporary or permanent?

Official safety warnings state that certain serious side effects of fluoroquinolones, such as peripheral neuropathy (nerve damage) and effects on the tendons, muscles, joints, and nervous system, have been reported as being disabling and potentially permanent.


Q: What if I forget to take Zidalev for a whole day?

The regulatory patient guidance advises not to take a double dose to make up for any missed dose. Patients are generally advised, in the event of a significant missed dose, that this is a matter for discussion with their healthcare provider.


Q: Is there a generic version of Zidalev available?

Zidalev is the brand name for the active ingredient levofloxacin. The active ingredient is currently available in a generic formulation that is officially recognized by regulatory bodies.


Q: Does Zidalev interact with common over-the-counter pain relievers?

The official interaction information warns that when Zidalev is used concurrently with certain non-steroidal anti-inflammatory drugs (NSAIDs), such as fenbufen, there is a potential for a pronounced lowering of the cerebral seizure threshold. This effect is described as a potential for a pronounced lowering of the cerebral seizure threshold.


Q: Is Zidalev safe to use if I have a history of liver problems?

Official documents advise caution for patients with existing liver disease as part of the safety profile. Severe and sometimes fatal liver injury, including cases of hepatic failure, is listed as a rare, serious adverse reaction associated with the medication.


Q: Are allergic reactions to Zidalev common?

Serious allergic (hypersensitivity) reactions, such as angioedema or anaphylactic shock, are described in the regulatory documents as possible. These severe reactions are typically classified as rare or of unknown frequency in clinical reports.

How should Zidalev be stored and disposed of?

Zidalev (levofloxacin) must be stored and handled according to specific regulatory requirements to maintain product stability.

Storage Requirements

Oral tablets and solution must be stored at Controlled Room Temperature, specifically 20°C to 25°C (68°F to 77°F), with excursions permitted up to 30°C. The medication must be kept in its original container and be protected from light.

Additionally, all forms of Zidalev must be stored out of the reach and sight of children.

Disposal Instructions

Unused or expired Zidalev should be taken to a drug take-back program or an authorized collection site. If no take-back program is available, the medicine must be mixed with an unappealing substance, sealed in a plastic bag, and placed in household trash. Do not flush the medicine down the toilet or pour it down a drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zidalev found in:

A-Z Index: